Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317775 | 0.75 | LMNA (0.34) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL5313188 | 0.71 | ESR1 (0.39) | CYP2C19 | |
| SCHEMBL5314916 | 0.70 | CHRNA7 (0.31) | — | |
| SCHEMBL5836381 | 0.69 | KMT2A (0.46) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL16146081 | 0.68 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPTMEN1KMT2A | |
| SCHEMBL5314215 | 0.68 | UGT2B7 (0.40) | TSHRMEN1KMT2A | |
| SCHEMBL5315971 | 0.68 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPTKDM4ETDP1 | |
| SCHEMBL13754055 | 0.67 | PDE2A (0.37) | ALDH1A1MAPK1CYP2C19 | |
| SCHEMBL27733971 | 0.67 | KMT2A (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL16146074 | 0.66 | ALDH1A1 (0.38) | ALDH1A1TSHRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314246-B2 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20090216025-A1 | Catalytic reactions involving alkenes | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216025-A1 | Catalytic reactions involving alkenes | ADH5, ADH1C, ADH1A | ALDH1A1 15/4885TSHR 4045/4885MAPT 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.